ERBB2 and breast carcinoma: As shown in Table 1, the largest patient group comprised those with luminal A (2628, 41.1%), followed by luminal B (2181, 34.1%), HER2‐enriched (883, 13.8%) and triple‐negative (704, 11.0%) breast cancer.